Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aniling develops next-generation genomic and epigenomic sequencing solutions to enable precision medicine in oncology. Their patented GEUS technology allows simultaneous genome and epigenome analysis from a single sample, overcoming key limitations of traditional DNA sequencing. The company’s lead products include the GEUS-LB liquid biopsy test for minimally invasive tumor DNA detection, with a focus on early cancer diagnosis, disease monitoring, and precision treatment decisions. They have particular emphasis on colorectal cancer and hematological malignancies such as CLL.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aniling.